Aptevo and Niowave Form 50/50 Radiopharmaceutical Oncology Partnership, Niowave Takes 7.9% Equity Stake
APVO sits 31% above its 52-week low of $3.8.
Summary
Aptevo Therapeutics and Niowave Inc. announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Niowave made an initial equity investment, acquiring a 7.9% ownership stake in Aptevo, with potential to increase to 19.99%. This partnership, which follows an 8-K filed on May 27th, marks Aptevo's entry into the high-growth radiopharmaceutical therapy market. The equity investment provides crucial capital and validation for Aptevo, a company that recently reported a going concern warning and significant cash burn. This collaboration offers a capital-efficient path to advance new cancer treatments.
At the time of this announcement, APVO was trading at $4.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $3.80 to $235.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: EQS.